en · de · es · pt
lab-handbook.peptides5388.com › Info › Background And Mechanism Of Sr9009 — What the Evidence Shows

Background And Mechanism Of Sr9009 — What the Evidence Shows

By Editorial Desk · published 2025-08-26 · last reviewed 2025-09-12 · Info

circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Related pages on this site

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

SR9009 Identity and Mechanism

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Reference notes

=== Modern Levantine groups with Israelite ancestry === Samaritans and Jews descend from the Israelites. With regard to the Jewish diaspora, it is held that each Jewish community originates from exiled Israelite settlement in various parts of the world, particularly as a result of the Jewish–Roman wars. It is also argued that some Palestinian people are similarly descended from those Israelites who were not exiled from the region and who consequently converted to Christianity under the Byzantine Empire and then to Islam following the Arab conquest of the Levant, except for Palestinian Jews and present-day Samaritans.

While transformed, he wields the D-Sword Vega (ディーソード・ベガ, Dī Sōdo Bega), which possesses a gun function and allows him to perform the Vega Tornado Slash (ベガトルネードスラッシュ, Bega Torunēdo Surasshu) attack and the Vega Slash (ベガスラッシュ, Bega Surasshu) finisher. He also rides the S.P.D. Helicopter (S.P.D.ヘリコプター, Esu Pī Dī Herikoputā). Doggie Kruger is voiced by Tetsu Inada (稲田 徹, Inada Tetsu).

Insect infestations, food shortages, and the destruction of provisions by rain and humidity presented ongoing challenges. Despite these hardships, Humboldt remained healthy and productive, documenting his scientific observations. Progressing up the Orinoco, the expedition reached Pararuma, where they met missionaries and Father Bernardo Zea, missionary of Atures and Maipures, who agreed to guide them further. Due to the rapids, a smaller canoe was acquired. The new canoe, hollowed from a single tree, was forty feet long and less than three feet wide. The arrangement left little space, resulting in cramped conditions for the passengers, supplies, and animal specimens. Native canoemen occupied the bow, and a mulatto servant from Cumana managed provisions and cooking. Insects continued to be a significant nuisance, and local methods of mitigation included sleeping in smoke-filled ovens, burying oneself in sand, or using mud and turtle oil as repellents. Humboldt also observed the use of rubber stoppers provided by local Natives. As the river narrowed, navigation through the Great Cataracts of Atures and Maipures required both paddling and hauling the canoe overland. Humboldt and Bonpland stayed at Father Zea’s mission during this process, where they observed a declining Native population, poor living conditions, and ongoing disease. Insect bites became a dominant hardship. Beyond the cataracts, the expedition entered little-documented territory.

== Efficacy and side effects == Cholinergic nerves play an important role in the normal function of the central nervous, endocrine, neuromuscular, immunological, and respiratory system. As all cholinergic fibers contain high concentrations of ACh and AChE at their terminals, inhibition of AChE can impair their function. So exposure to azinphosmethyl, whereas it inhibits AChEs, may disturb a lot of important systems and may have various effects. In the autonomic nervous system, accumulation of acetylcholine leads to the overstimulation of muscarinic receptors of the parasympathetic nervous system. This can affect exocrine glands (increased salivation, perspiration, lacrimation), the respiratory system (excessive bronchial secretions, tightness of the chest, and wheezing), the gastrointestinal tract (nausea, vomiting, diarrhea), the eyes (miosis, blurred vision) and the cardiovascular system (decrease in blood pressure, and bradycardia). Overstimulation of the nicotinic receptors in the para- or sympathetic nervous system may also cause adverse effects on the cardiovascular system, such as pallor, tachycardia and increased blood pressure. In the somatic nervous system, accumulation of acetylcholine may cause muscle fasciculation, paralysis, cramps, and flaccid or rigid tone. Overstimulation of the nerves in the central nervous system, specifically in the brain, may result in drowsiness, mental confusion and lethargy. More severe effects on the central nervous system include a state of coma without reflexes, cyanosis and depression of the respiratory centers.

Sources: en.wikipedia.org

Reference notes

=== Part Two === The Purchase Brothers had initially planned to release the second part of the film in early to mid-March 2009, but the large number of emails and phone calls the two received regarding the first part slowed development of the second. According to teaser clips at the end of the first part, the two Resistance soldiers will be joined by two additional characters, one of them a heroine, and will come into contact with headcrab zombies. The Purchase Brothers cited on their YouTube profile page that a new secret film project has heavily hampered their progress in completing Part Two, although it would be released in the near future. Another teaser clip was released on YouTube on October 13, 2009. Part Two was released on YouTube on August 19, 2011. The clip was quickly removed for unknown reasons by the end of the same day with no further comment on why it was removed. It was re-uploaded on August 24, 2011.

(CH2CH2)O + PCl5 → Cl–CH2CH2–Cl + POCl3 Other dichloro derivatives of ethylene oxide can be obtained by combined action of sulfuryl chloride (SOCl2) and pyridine and of triphenylphosphine and carbon tetrachloride. Phosphorus trichloride reacts with ethylene oxide forming chloroethyl esters of phosphorous acid:

=== Protein degradation === The ubiquitin-proteasome system (UPS) figures prominently in protein degradation. The 26S proteasome consists of a catalytic subunit (the 20S core particle), and a regulatory subunit (the 19S cap). Poly-ubiquitin chains tag proteins for degradation by the proteasome, which causes hydrolysis of tagged proteins into smaller peptides. Physiologically, PI31 attacks 20S catalytic domain of 26S Proteasome that results in decreased proteasome activity. (ADP-ribosyl)transferase Tankyrase (TNKS) causes ADP-ribosylation of PI31 which in turn increases the proteasome activity. Inhibition of TNKs further shows the reduced 26S Proteasome assembly. Therefore, ADP-ribosylation promotes 26S Proteasome activity in both Drosophila and human cells.

In the aftermath of World War II, the USAAF consolidated much of its wartime combat force and selected the P-51 as a "standard" piston-engined fighter, while other types, such as the P-38 and P-47, were withdrawn or given substantially reduced roles. As the more advanced (P-80 and P-84) jet fighters were introduced, the P-51 was also relegated to secondary duties. In 1947, the newly formed USAF Strategic Air Command employed fighter Mustangs alongside F-6 Mustangs and F-82 Twin Mustangs, due to their range capabilities. In 1948 a new designation scheme for USAF aircraft was introduced, with the prefix "P-" for "pursuit" changed to "F-" for "fighter" and the existing "F-" designation for photographic reconnaissance replaced with "RF-;" Mustang variants still in service in the USAF or Air National Guard (ANG) when the system was changed included: F-51B, F-51D, F-51K, RF-51D (formerly F-6D), RF-51K (formerly F-6K) and TRF-51D (two-seat trainer conversions of F-6Ds). By 1950, the majority of the USAF's Mustangs had become surplus to requirements and had been placed in storage or transferred to the Air Force Reserve and the ANG.

Originally launched in February 2008, the SBKB is a free resource that provides information on protein sequence and keyword searching, as well as modules describing target selection, experimental protocols, structure models, functional annotation, metrics on overall progress, and updates on structure determination technology. Like the PDB, it is directed by Dr. Helen M. Berman and hosted at Rutgers University. The PSI Materials Repository, established in 2006 at the Harvard Institute of Proteomics, stores and ships PSI-generated plasmid clones. Clones are sequence-verified, annotated and stored in the DNASU Plasmid Repository, currently located at the Biodesign Institute at Arizona State University. As of September 2011, there are over 50,000 PSI-generated plasmid clones and empty vectors available for request through DNASU in addition to over 147,000 clones generated from non-PSI sources. Plasmids are distributed to researchers worldwide. Now called the PSI:Biology Materials Repository, this resource has a five-year budget of $5.4 million and is under the direction of Dr. Joshua LaBaer, who moved to Arizona State University in the middle of 2009, taking the PSI:Biology-MR with him.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

Network